-
GlaxoSmithKline’s first-quarter figures show the company is on track for the year
Analysis Latest results show that it's business as usual for pharmaceutical giant GlaxoSmithKline. Rupert Hargreaves casts his eyes over the numbers.
Analysis -
Why GSK should turn down Unilever’s billions
News Unilever has offered GSK £50bn for its consumer division. But while the cash will be a temptation, the deal is not in the interests of shareholders or of anyone else, says Matthew Lynn.
News -
Unilever slides and GSK bounces after GSK knocks back £50bn bid
News Unilever shares fell to their lowest level in around five years, after its £50bn takeover bid for GSK’s consumer health unit was rejected.
News -
Shake-up at GSK won’t placate investors
News GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance.
News -
A show of support for GlaxoSmithKline's hedge fund fight
News Several large shareholders have said that they will support GlaxoSmithKline in its battle with hedge fund Elliott Management.
News -
Activist investor Elliott takes takes a stake in Glaxo
News Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
News -
If you'd invested in: Renishaw and GlaxoSmithKline
Features Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
Features -
GSK: on the mend?
Features Glaxo’s chief executive has stepped down after nine years at the top. Has he left the pharma giant in good health? Alex Rankine reports.
Features -
A golden hello that says big companies aren't hearing us
Opinion When it comes to ridiculous executive pay, GlaxoSmithKline still doesn't get it, says Merryn Somerset Webb. But they're not the only ones.
Opinion
1
2